SG11201809786TA - Dna monoclonal antibodies targeting il-6 and cd126 - Google Patents

Dna monoclonal antibodies targeting il-6 and cd126

Info

Publication number
SG11201809786TA
SG11201809786TA SG11201809786TA SG11201809786TA SG11201809786TA SG 11201809786T A SG11201809786T A SG 11201809786TA SG 11201809786T A SG11201809786T A SG 11201809786TA SG 11201809786T A SG11201809786T A SG 11201809786TA SG 11201809786T A SG11201809786T A SG 11201809786TA
Authority
SG
Singapore
Prior art keywords
international
sequence
english
lane
monoclonal antibodies
Prior art date
Application number
SG11201809786TA
Other languages
English (en)
Inventor
David Weiner
Original Assignee
Univ Pennsylvania
Wistar Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Pennsylvania, Wistar Inst filed Critical Univ Pennsylvania
Publication of SG11201809786TA publication Critical patent/SG11201809786TA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0066—Manipulation of the nucleic acid to modify its expression pattern, e.g. enhance its duration of expression, achieved by the presence of particular introns in the delivered nucleic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0009—Galenical forms characterised by the drug release technique; Application systems commanded by energy involving or responsive to electricity, magnetism or acoustic waves; Galenical aspects of sonophoresis, iontophoresis, electroporation or electroosmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/248—IL-6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
SG11201809786TA 2016-05-05 2017-05-05 Dna monoclonal antibodies targeting il-6 and cd126 SG11201809786TA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662332377P 2016-05-05 2016-05-05
PCT/US2017/031193 WO2017192933A1 (en) 2016-05-05 2017-05-05 Dna monoclonal antibodies targeting il-6 and cd126

Publications (1)

Publication Number Publication Date
SG11201809786TA true SG11201809786TA (en) 2018-12-28

Family

ID=60203626

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201809786TA SG11201809786TA (en) 2016-05-05 2017-05-05 Dna monoclonal antibodies targeting il-6 and cd126
SG10202011023YA SG10202011023YA (en) 2016-05-05 2017-05-05 Dna monoclonal antibodies targeting il-6 and cd126

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG10202011023YA SG10202011023YA (en) 2016-05-05 2017-05-05 Dna monoclonal antibodies targeting il-6 and cd126

Country Status (12)

Country Link
US (1) US20190192692A1 (es)
EP (1) EP3452106A4 (es)
JP (2) JP7311113B2 (es)
KR (2) KR20230058733A (es)
CN (1) CN109789224A (es)
AU (2) AU2017261292B2 (es)
BR (1) BR112018072697A2 (es)
CA (1) CA3023089A1 (es)
EA (1) EA201892524A1 (es)
MX (1) MX2018013523A (es)
SG (2) SG11201809786TA (es)
WO (1) WO2017192933A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110167584B (zh) * 2016-11-07 2024-06-07 威斯塔解剖学和生物学研究所 用于针对莱姆病的dna抗体构建体
KR102635888B1 (ko) 2019-03-19 2024-02-15 엘지전자 주식회사 공기청정기
EP4277929A1 (en) * 2021-01-14 2023-11-22 Translate Bio, Inc. Methods and compositions for delivering mrna coded antibodies

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2308888T (pt) * 2001-11-14 2017-05-03 Janssen Biotech Inc Anticorpos anti-il-6, composições, métodos e utilizações
PT1960430E (pt) * 2005-12-09 2015-01-05 Ucb Pharma Sa Moléculas de anticorpo com especificidade para il-6 humana
CA2657763C (en) * 2006-08-03 2016-05-31 Vaccinex Inc. Anti-il-6 monoclonal antibodies and uses thereof
DK2297202T3 (en) 2008-05-13 2016-03-21 Novimmune Sa ANTI-IL-6 / IL-6R ANTIBODIES AND PROCEDURES FOR USE THEREOF
WO2011084714A2 (en) 2009-12-17 2011-07-14 Biogen Idec Ma Inc. STABILIZED ANTI-TNF-ALPHA scFv MOLECULES OR ANTI-TWEAK scFv MOLECULES AND USES THEREOF
CA2818813C (en) 2010-11-23 2020-10-06 Alder Biopharmaceuticals, Inc. Anti-il-6 antibodies for the treatment of oral mucositis
JP6898060B2 (ja) * 2012-12-13 2021-07-07 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア Ｄｎａ抗体構築物およびその使用方法
CN110559435B (zh) 2013-09-11 2023-10-20 伊戈尔生物药品股份有限公司 包含离子性液体的液体蛋白质制剂

Also Published As

Publication number Publication date
JP2023086734A (ja) 2023-06-22
AU2017261292B2 (en) 2024-06-06
EP3452106A1 (en) 2019-03-13
BR112018072697A2 (pt) 2019-02-19
AU2017261292A1 (en) 2018-12-20
KR20230058733A (ko) 2023-05-03
SG10202011023YA (en) 2020-12-30
US20190192692A1 (en) 2019-06-27
EP3452106A4 (en) 2020-01-08
CA3023089A1 (en) 2017-11-09
AU2024203109A1 (en) 2024-05-30
KR20190031439A (ko) 2019-03-26
JP7311113B2 (ja) 2023-07-19
MX2018013523A (es) 2019-06-10
EA201892524A1 (ru) 2019-04-30
CN109789224A (zh) 2019-05-21
WO2017192933A1 (en) 2017-11-09
JP2019518074A (ja) 2019-06-27

Similar Documents

Publication Publication Date Title
SG11201903882VA (en) Il-2 variants for the treatment of autoimmune diseases
SG11201810023QA (en) Anti-tim-3 antibodies and methods of use thereof
SG11201806496SA (en) Antigen binding proteins that bind pd-l1
SG11201810933QA (en) Anti-c5 antibodies and uses thereof
SG11201909873TA (en) Dynamic autonomous vehicle servicing and management
SG11201808242UA (en) Methods for inhibiting angiogenesis in a subject in need thereof
SG11201809879WA (en) Novel antibodies specifically binding to zika virus epitopes and uses thereof
SG11201810525XA (en) Anti-gitr antibodies and uses thereof
SG11201907753TA (en) Bispecific binding molecules that are capable of binding cd137 and tumor antigens, and uses thereof
SG11201909081YA (en) Anti-ilt4 antibodies and antigen-binding fragments
SG11201909949XA (en) Targeted immunotolerance
SG11201809789SA (en) Dna monoclonal antibodies targeting checkpoint molecules
SG11201808724SA (en) Anti-tim-3 antibodies and compositions
SG11201805888SA (en) Cyclic dinucleotides for treating conditions associated with sting activity such as cancer
SG11201908238SA (en) Anti-c5 antibodies and uses thereof
SG11201906192SA (en) Methods of treating cancer with anti-pd-1 antibodies
SG11201900201YA (en) Methods for quantitating individual antibodies from a mixture
SG11201811363YA (en) Anti-zika virus antibodies and methods of use
SG11201908056QA (en) Anti-par2 antibodies and uses thereof
SG11201910134SA (en) Stable formulations of anti-ctla4 antibodies alone and in combination with programmed death receptor 1 (pd-1) antibodies and methods of use thereof
SG11201803703UA (en) Anti-complement factor c1q fab fragments and uses thereof
SG11201808152PA (en) Dna antibody constructs and method of using same
SG11201906853QA (en) Anti-rsv monoclonal antibody formulation
SG11201809778TA (en) Dna antibody constructs for use against pseudomonas aeruginosa
SG11201903771XA (en) Binding molecules specific for asct2 and uses thereof